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In type 1 diabetes, cytotoxic CD8+ T cells with specificity for b cell autoantigens are found in
the pancreatic islets, where they are implicated in the destruction of insulin-secreting b cells.
In contrast, the disease relevance of b cell–reactive CD8+ T cells that are detectable in the
circulation, and their relationship to b cell function, are not known. Here, we tracked
multiple, circulating b cell–reactive CD8+ T cell subsets and measured b cell function
longitudinally for 2 years, starting immediately after diagnosis of type 1 diabetes. We found
that change in b cell–specific effector memory CD8+ T cells expressing CD57 was
positively correlated with C-peptide change in subjects below 12 years of age. Autoreactive
CD57+ effector memory CD8+ T cells bore the signature of enhanced effector function
(higher expression of granzyme B, killer-specific protein of 37 kDa, and CD16, and reduced
expression of CD28) compared with their CD57– counterparts, and network association
modeling indicated that the dynamics of b cell–reactive CD57+ effector memory CD8+ T cell
subsets were strongly linked. Thus, coordinated changes in circulating b cell–specific CD8+
T cells within the CD57+ effector memory subset calibrate to functional insulin reserve in
type 1 diabetes, providing a tool for immune monitoring and a mechanism-based target for
immunotherapy.
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Introduction
Type 1 diabetes is an autoimmune disease in which insulin-secreting 
β cells of the pancreatic islets are selectively destroyed (1, 2). CD8+ T 
cells are regarded as critical players in mediating β cell destruction, 
for a number of reasons. First, CD8+ T cells dominate the lympho-
cytic infiltrate observed in the islets of type 1 diabetes patients, and 
this pathological lesion is associated with upregulation of HLA class 
I molecules that has the potential to enhance CD8+ T cell–β cell inter-
actions (3–5). Second, CD8+ T cells recognizing β cell autoantigens 
that include preproinsulin (PPI), tyrosine phosphatase–like insu-
linoma antigen (IA2), islet-specific glucose-6-phosphate catalytic 
subunit–related protein (IGRP), glutamic acid decarboxylase-65 
(GAD65), and insulin B chain (InsB) are present in the blood and 
islets of individuals with type 1 diabetes (3, 6–8). And finally, CD8+ 
T cell clones recognizing epitopes of PPI and GAD65 kill isolated β 
cells in vitro, exemplifying the potential for CD8+ T cells to constitute 
major effectors of β cell death (9, 10).
Thus, at the level of disease pathogenesis, the CD8+ T cell/
HLA class I pathway provides a compelling framework for a 
mechanistic understanding of β cell destruction leading to type 
1 diabetes (9, 11, 12). As a result, considerable effort has been 
expended to define CD8+ T cell epitopes presented by β cells, 
and measure reactivity against them in the peripheral blood, 
using highly sensitive technologies such as fluorescent, peptide-
loaded HLA (pHLA) tetramers, which are designed to identify 
autoreactive CD8+ T cells at single-cell resolution. The major cri-
tique of such an approach is that the relationship between tissue- 
infiltrating and circulating immune cells is poorly defined. At 
best, if there is programmed recirculation of relevant β cell– 
specific CD8+ T cells, then studying their blood phase would pro-
vide a means to understand what is happening in the tissues. At 
worst, examining circulating T cells could be entirely mislead-
ing, if they bear little or no relation to the relevant tissue pathol-
ogy. In the absence of an answer to this conundrum, we reasoned 
that examining the relationship between circulating β cell– 
specific CD8+ T cells and functional insulin-secreting capacity as 
they change over time would provide an important step toward 
addressing this knowledge gap. Identification of a relationship 
between peripheral immune changes and metabolic activity in the 
target organ would be a major advance in developing the former 
into surrogate markers for the latter. This could yield useful bio-
markers of β cell decline and further strengthen the mechanistic 
link between autoreactive CD8+ T cells and disease pathogenesis.
Therefore, in this study we sought to test the hypothesis that 
the frequency or functional phenotype of circulating β cell–specific 
CD8+ T cells correlates with the rate of decline of functional insulin 
reserve following diagnosis of type 1 diabetes (13–16). To achieve 
this and ensure high quality of biological samples and metadata, 
we made use of a longitudinal collection made over a 2-year period 
from patients with a new diagnosis of type 1 diabetes who were 
enrolled into the placebo arms of clinical intervention trials.
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The predicted C-peptide change per T cell change for each of the 
significantly correlated β cell–specific T cell populations is given in 
Figure 2A and Table 2, and is calculated as the log C-peptide change 
from baseline per 1% increase in T cells. For example, in the case 
of PPI-specific CD57+ effector memory CD8+ T cells, a 1% increase 
from baseline is associated with a log C-peptide increase from base-
line of 0.206. In this way, the model provides estimates for the effect 
of CD8+ T cell change on the change in C-peptide levels.
In order to further investigate the link between tissue antigen 
levels and circulating T cells, we examined whether the CD8+ T 
cell subsets that were significantly correlated with C-peptide log 
change from baseline were also correlated with C-peptide levels. 
We found that the InsB-specific CD57+ effector memory and InsB-
specific effector memory CD8+ T cell subsets correlated with abso-
lute C-peptide levels (Supplemental Table 3).
In contrast to the significant associations observed between 
antigen-specific CD8+ T cell subsets and C-peptide change, none 
of the total CD8+ T cell subsets were found to be significantly asso-
ciated with C-peptide change.
Virus-specific autoreactive CD8+ T cell subsets correlate with 
C-peptide change over time. We observed that 9 virus-specific T 
cell subsets were significantly correlated with C-peptide change 
(Figure 2B and Table 2). In contrast with the positive correla-
tions observed between β cell–specific memory T cell subsets 
and C-peptide, the majority (7 of 9) of the virus-specific subsets 
were negatively correlated with C-peptide change, indicating that 
C-peptide falls as T cell levels increase, or C-peptide increases 
as T cell levels fall. The phenotype of the significantly correlated 
virus-specific subsets encompassed several T cell subsets, includ-
ing CMV-specific transitional memory, central memory, effector 
memory, CD57+ effector memory, and CD57– effector memory 
subsets; influenza-specific transitional memory and CD57– effec-
Results
Specific autoreactive CD8+ T cell subsets correlate with C-peptide 
change over time. Antigen-specific CD8+ T cells were identified 
by pHLA class I tetramer staining of peripheral blood mononu-
clear cell (PBMC) samples from newly diagnosed type 1 diabetes 
patients collected longitudinally over 2 years at 6-month intervals 
(see Supplemental Tables 1 and 2 for patient information; supple-
mental material available online with this article; https://doi.
org/10.1172/JCI120555DS1). We characterized the phenotype of 
CD8+ T cells specific for 5 β cell antigens (PPI, IA2, InsB, GAD, and 
IGRP) and, for comparison, 3 viral antigens (influenza, CMV, and 
EBV) using pHLA class I tetramers (Figure 1 and Table 1). In addi-
tion, we analyzed the T cell subsets within the total CD8+ T cell 
population. As a readout of β cell function we used measurements 
of C-peptide, a by-product of insulin production that is released 
into the circulation in amounts equimolar with insulin, and is con-
sidered a robust surrogate of β cell function. Mixed-effects general 
linear modeling was used to explore whether there was a relation-
ship between CD8+ T cell subsets and C-peptide change over 2 
years. For each CD8+ T cell subset analyzed, the model predicted 
the amount of C-peptide change that would result from a given 
change in T cells. We report these data as slopes that are estimates 
of the average C-peptide loss per unit change in T cell.
Of the β cell–specific T cell subsets, 5 were found to be posi-
tively correlated with C-peptide change (Figure 2A). Strikingly, 
these were predominantly effector memory T cell subsets (4 of 
5) expressing the terminal differentiation marker CD57 (3 of 5), 
spanning multiple β cell specificities (for PPI, GAD, and InsB). 
Additionally, the IA2-specific transitional memory subset (a 
phenotype intermediate between central memory and effector 
memory) was positively correlated with C-peptide change. When 
data were pooled from all the β cell–specific (PPI-, InsB-, IGRP-, 
IA2-, and GAD-specific) CD8+ T cells examined, the pooled β cell– 
specific CD57+ effector memory CD8+ T subset was also positively 
correlated with C-peptide change.
The positive correlations observed between β cell–specific T cell 
subsets and C-peptide indicate that C-peptide levels increase as T 
cell levels increase, and C-peptide levels fall as T cell levels fall. To 
illustrate the nature of this relationship, the dynamics of PPI-specific 
CD57+ effector memory CD8+ T cells and predicted C-peptide levels 
over 2 years are shown for individual patients in Supplemental Fig-
ure 1. Interestingly, concomitant increases in C-peptide and β cell–
specific CD57+ effector memory CD8+ T cell levels were observed 
in several patients at the 6-month visit. This is likely to reflect the 
“honeymoon period” experienced by some patients after commenc-
ing insulin injection, which is characterized by greater C-peptide 
secretion. This suggests that the functional recovery of β cells pro-
motes the appearance of CD57+ effector memory β cell–specific 
CD8+ T cells in the blood. As illustrated in Supplemental Figure 1, 
in the majority of subjects, a decrease in β cell–specific CD57+ effec-
tor memory CD8+ T cells was accompanied by a fall in predicted 
C-peptide levels. This is consistent with β cell destruction medi-
ated by highly cytotoxic T cells, levels of which decline with loss of 
antigen. Thus the positive relationships observed between β cell– 
specific CD57+ effector memory CD8+ T subsets and C-peptide 
change reflect a prototypical antigen-driven immune response dur-
ing which levels of T cells and their target covary.
Table 1. HLA-A*02– and HLA-A*24–restricted CD8+ T cell epitopes
Epitope HLA class I restriction Sequence
PPI
15–24
A*02 ALWGPDPAAA
PPI
3–11
A*24 LWMRLLPLL
InsB
10–18
A*02 HLVEALYLV
InsB
15–24
A*24 LYLVCGERGF
IA-2
797–805
A*02 MVWESGCTV
GAD65
114–123
A*02 VMNILLQYVV
IGRP
265–273
A*02 VLFGLGFAI
Influenza A M1
58–66
A*02 GILGFVFTL
CMV pp65
495–503
A*02 NLVPMVATV
CMV pp65
248–257
A*24 AYAQKIFKIL
EBV BMLF1
280–288
A*02 GLCTLVAML
EBV BMLF1
198–206
A*24 TYPVLEEMF
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specific CD8+ T cell subsets remained significantly associated 
with C-peptide change.
In order to further investigate the link between tissue antigen 
levels and circulating virus-specific T cells, we examined whether 
the CD8+ T cell subsets that were significantly correlated with 
C-peptide log change from baseline were also correlated with 
C-peptide levels. We found that the CMV transitional memory and 
CMV effector memory CD8+ T cell subsets correlated with abso-
lute C-peptide levels (Supplemental Table 3).
Effects of age, HLA, and autoantibodies. We next explored how 
the relationship between C-peptide and CD8+ T cell populations 
compared between patients of different ages. For this purpose we 
divided patients into 3 groups of <12 years, 12–17 years, and >17 
tor memory subsets; and EBV-specific central memory and ter-
minal effector subsets. The predicted C-peptide change per unit 
increase in T cells for each of the significantly correlated virus-
specific T cell populations is given in Figure 2B and Table 2.
The phenotypic heterogeneity observed in the significantly 
correlated virus-specific T cell subsets contrasts with the clear 
effector memory–dominant pattern observed for the signifi-
cantly correlated β cell–specific T cell subsets. It appears likely 
that this difference reflects the different effects of persistent 
antigenic exposure (in the case of β cells) compared with more 
complex episodic virus encounters that may occur at different 
times in different subjects. Importantly, we observed that after 
adjustment for multiple comparisons, many of the antigen- 
Figure 1. Identification of antigen-
specific CD8+ T cell subsets. (A) 
Representative staining of PBMCs 
with peptide-loaded HLA-A*02 and 
HLA*A-24 tetramers to identify 
CD8+ T cells specific for β cell and 
virus epitopes. Tetramer-positive 
CD8+ T cell frequencies were 
calculated as the percentage of the 
total CD8+ T cell population and 
are displayed in the upper right 
quadrants of the flow cytometry 
plots. (B) Schematic of the CD8+ 
T cell subsets analyzed and the 
cell surface markers used for their 
definition.
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tive and 18% HLA-A*24 positive in the 12–17 years group; 83% 
HLA-A*02 positive and 17% HLA-A*24 positive in the >17 years 
group). The autoantibody profiles were not significantly different 
between the 3 age groups. In subjects of <12 years, 12–17 years, and 
>17 years, the respective mean and SD autoantibody titers at base-
line were 0.25 (0.32), 0.23 (0.30), and 0.36 (0.61) for mIAA; 0.16 
(0.14), 0.19 (0.24), and 0.10 (0.11) for GAD65; and 0.33 (0.26), 
0.53 (0.46), and 0.30 (0.35) for ICA512.
CD57+ effector memory CD8+ T cells have enhanced cytotoxic 
potential. Having uncovered a strong positive relationship between 
the β cell–specific CD57+ effector memory CD8+ T cell subset and 
C-peptide change, we sought to gain further mechanistic insights 
by examining the gene expression of the CD57+ effector memory 
cell subset in comparison with effector memory cells lacking CD57. 
We performed RNA sequencing of CD57+ and CD57– effector mem-
ory CD8+ T cells sorted from 5 male recent-onset type 1 diabetes 
patients, and found that 315 genes were differentially expressed 
between the 2 effector memory populations [FDR-adjusted P < 
0.05, log2(fold change) > 1]. Differential gene expression showed 
consistent patterns across each of the 5 patients analyzed (Fig-
ure 3A). As indicated in the volcano plot (Figure 3B), the CD57+ 
effector memory population showed a significant enrichment of 
genes associated with cytotoxicity, including granzyme B (GZMB), 
granzyme H (GZMH), killer-specific protein of 37 kDa (KSP37), G 
protein–coupled receptor 56 (GPR56), and CD16 (17–22), com-
pared with CD57– effector memory cells, indicating a gene sig-
nature associated with enhanced cytotoxic effector function. 
Interestingly, the most highly upregulated gene in CD57+ effec-
tor memory CD8+ T cells was serine protease 23 (PRSS23), which 
has been reported in cytotoxic T cells but whose function remains 
unknown (23, 24). Moreover, in comparison with CD57– effector 
memory cells, the CD57+ subset showed a relative downregulation 
of transcripts for the costimulation molecule CD28, and genes 
years (Supplemental Table 2). Strikingly, it emerged that the rela-
tionships observed when all patients were included in the analysis 
reached statistical significance only in the youngest patient group 
of <12 years but not the older age groups (Supplemental Figure 2 
and Table 3). The HLA profiles of the subjects in the 3 age groups 
were not significantly different (73% HLA-A*02 positive and 27% 
HLA-A*24 positive in the <12 years group; 82% HLA-A*02 posi-
Figure 2. β Cell–specific and virus-specific CD8+ T cell subsets are significantly correlated with longitudinal C-peptide change. (A) Five β cell–specific 
CD8+ T cell subsets are positively correlated with C-peptide. Additionally, when data are pooled from all β cell–specific (PPI-, InsB-, GAD-, IA2-, and 
GAD-specific) CD8+ T cells, the CD57+ effector memory CD8+ T subset (“Pooled β cell–specific CD57+ EM”) is positively correlated with C-peptide. (B) Nine 
virus-specific CD8+ T cell subsets are correlated with longitudinal C-peptide change. Seven of nine are negatively correlated; two are positively correlated. 
The predicted log C-peptide change from baseline per 1% increase in each T cell subset is plotted. Thirty-eight subjects were studied, and relationships 
between T cell and C-peptide changes from baseline across time were analyzed with mixed-effects general linear models. To understand the variance of 
these data, note that the P values indicate the standard error, and for P < 0.05, a 95% confidence interval would not include the value zero. CM, central 
memory; TM, transitional memory; EM, effector memory; TE, terminal effector. Relationships between T cell and C-peptide changes from baseline across 
time were analyzed with mixed-effects general linear models. P < 0.05 (indicated by dotted horizontal line) was regarded as significant.
Table 2. Antigen-specific CD8+ T cell subsets significantly 
correlated with C-peptide
C-peptide change  
per T cell change
P
β Cell–specific CD8+ T cell subset
   PPI CD57+ effector memory 0.206 0.002
   GAD CD57+ effector memory 0.231 0.003
   InsB CD57+ effector memory 0.112 0.008
   InsB effector memory 0.066 0.012
   IA2 transitional memory 0.052 0.014
Virus-specific CD8+ T cell subset
   CMV effector memory –0.116 3.7 × 10–6
   Influenza CD57– effector memory –0.348 1.3 × 10–4
   Influenza transitional memory 0.076 1.9 × 10–4
   CMV CD57+ effector memory –0.092 0.001
   CMV transitional memory –0.035 0.002
   CMV CD57– effector memory –0.150 0.005
   EBV terminal effector 0.026 0.017
   EBV central memory –0.027 0.020
   CMV central memory –0.052 0.029
C-peptide change per T cell change was calculated as log C-peptide 
change from baseline per 1% increase in T cells. P < 0.05 was considered 
statistically significant.
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CD57+ effector memory CD8+ T cells show enhanced clonal expan-
sion. To further understand the relationship between the CD57+ 
and CD57− effector memory CD8+ T cell compartments, we ana-
lyzed T cell receptor β chain (TCRβ) sequences derived from the 
same RNA sequencing data as that used for gene expression analy-
sis. There were no significant differences in the number of cells 
sorted or in the number of total TCRβ sequences obtained from 
the sorted CD57+ and CD57− effector memory CD8+ T cell popu-
lations, allowing unbiased comparison of their TCRβ repertoires 
(Supplemental Table 4). Comparison of CD57+ and CD57− effec-
tor memory T cell populations revealed that the diversity of TCRβ 
sequences was significantly lower in CD57+ compared with CD57− 
effector memory T cell samples, indicating a greater enrichment 
of particular clonotypes in the CD57+ compartment (Figure 4A). 
Accordingly, in CD57+ effector memory T cell samples, clones 
were more highly expanded compared with CD57− effector mem-
ory T cell samples (Figure 4B). In addition, a high level of over-
lap in TCRβ sequences was observed between paired CD57+ and 
CD57– effector memory T cell samples within individual patients, 
suggesting that both populations have a similar repertoire (Figure 
4C). This relationship implies that expanded CD57+ effector mem-
ory T cell clones arise from the CD57– effector memory T cell pool 
as a result of ongoing or repeated exposures to antigen specificities 
requiring a cytotoxic response.
Antigen-specific CD8+ T cell subsets are associated with each other 
and with C-peptide change over time. We explored the longitudinal 
relationships between all of the CD8+ T cell populations analyzed 
(antigen-specific and total) using cluster analysis based on pair-
wise correlations of T cell populations over time. We observed that 
designated CD8+ T cell subsets cluster together irrespective of 
their antigen specificity (Figure 5). Notably, we observed that the 
CD57+ effector memory and total effector memory T cell subsets 
with multiple β cell specificities were the most strongly clustered 
 associated with memory and self-renewal (25–28) including IL7R, 
IL2, Satb1, and P2ry14. CD57+ effector memory cells showed 
upregulation of the transcription factor ZEB2, which drives termi-
nal CD8+ T cell differentiation and represses IL2 and IL7R (29). 
These data indicate that the CD57+ effector memory compart-
ment is a highly differentiated, antigen-experienced population 
capable of exerting immediate cytotoxic effects, in contrast to 
the CD57– effector memory compartment, which represents a 
self-renewing pool of memory T cells. The difference in cytotoxic 
potential between the CD57+ and CD57– effector memory CD8+ 
T cell populations suggested by these data is supported by gene 
ontology analysis, which reveals significant enrichment of T cell 
killing pathways within the genes differentially expressed between 
CD57+ and CD57– effector memory cells (Figure 3C).
To validate these findings at the protein level, and, impor-
tantly, to confirm that an enhanced cytotoxic effector gene signa-
ture was present in β cell–specific CD57+ effector memory CD8+ T 
cells as well as in the total effector memory CD8+ T cell pool, we 
compared the phenotype of PPI-specific CD57+ and CD57– effec-
tor memory T cells in PBMC samples obtained from recent-onset 
type 1 diabetes patients by flow cytometry. In accordance with the 
RNA sequencing data, we observed significantly higher expres-
sion of granzyme B, GPR56, killer-specific protein of 37 kDa, and 
CD16 and significantly lower expression of CD28 in CD57+ com-
pared with CD57– effector memory T cells specific for PPI (Fig-
ure 3D). Notably, we confirmed that, as observed from the RNA 
sequencing data, at the protein level, genes associated with T cell 
exhaustion, such as KLRG1 and LAG3, were not upregulated on 
CD57+ effector memory cells, indicating that this population is 
not associated with an exhausted phenotype (Figure 3D). These 
results suggest that β cell–specific CD57+ effector memory CD8+ 
T cells have enhanced cytotoxic potential and are therefore fully 
capable of driving β cell destruction.
Table 3. Antigen-specific CD8+ T cell subsets associated with C-peptide change in subjects grouped by age
<12 Years 12–17 Years >17 Years
C-peptide change  
per T cell change
P C-peptide change  
per T cell change
P C-peptide change  
per T cell change
P
β Cell–specific CD8+ T cell subset
   PPI CD57+ effector memory 0.206 0.002 0.003 0.787 0.016 0.719
   GAD CD57+ effector memory 0.231 0.003 0.011 0.745 –0.008 0.909
   InsB CD57+ effector memory 0.112 0.008 0.005 0.662 –0.030 0.456
   InsB effector memory 0.066 0.012 0.004 0.726 –0.014 0.681
   IA2 transitional memory 0.052 0.014 –0.006 0.684 –0.008 0.719
Virus-specific CD8+ T cell subset
   CMV effector memory –0.116 3.7 × 10–6 –0.011 0.529 0.027 0.494
   Influenza CD57– effector memory –0.348 1.3 × 10–4 0.047 0.163 –0.014 0.907
   Influenza transitional memory 0.076 1.9 × 10–4 4.12 × 10–4 0.945 0.002 0.887
   CMV CD57+ effector memory –0.092 0.001 –0.002 0.919 0.071 0.406
   CMV transitional memory –0.035 0.002 –0.003 0.769 0.012 0.632
   CMV CD57– effector memory –0.150 0.005 –0.022 0.459 0.036 0.609
   EBV terminal effector 0.026 0.017 0.014 0.648 0.067 0.372
   EBV central memory –0.027 0.020 0.003 0.742 –0.001 0.954
   CMV central memory –0.052 0.029 0.003 0.768 0.017 0.388
C-peptide change per T cell change was calculated as log C-peptide change from baseline per 1% increase in T cells. P < 0.05 was considered statistically significant.
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populations, as indicated in Figure 5 by their close proximity and 
connection by thick green lines representative of strong positive 
correlations. These observations indicate that the dynamics of β 
cell–reactive CD8+ T cell subsets, including CD57+ effector mem-
ory subsets, are correlated during disease progression and may 
have a synergistic effect in driving β cell destruction.
To further explore the relationship between combinations of β 
cell–specific CD8+ T cell subsets and C-peptide, we used canonical 
correlation analysis. This approach determined the combination 
of analytes most strongly correlated with C-peptide change from 
baseline by ascribing weightings to each T cell subset (canonical 
correlation coefficients, given in Tables 4–6). For each subject at 
each visit in the study, we formed a new variable by multiplying 
each of the CD8+ T cell subset frequencies by the corresponding 
numerical coefficient and summing these products; thus, the new 
variable represents a combination of multiple CD8+ T cell subset 
frequencies, referred to as a “canonical correlation score.” Canon-
ical correlation analysis was performed using β cell–specific CD8+ 
T cell data, virus-specific CD8+ T cell data, and total CD8+ T cell 
data. The β cell–specific and virus-specific CD8+ T cell canonical 
correlation scores were found to correlate strongly with C-peptide 
(both r = 0.75, P < 0.0001; Figure 6). In contrast, total CD8+ T cell 
population canonical correlation scores were much more weakly 
correlated with C-peptide (r = 0.28, P = 0.0005). Interestingly, 
for each of the canonical correlation analyses, the canonical cor-
relation scores exhibited a stronger correlation with C-peptide in 
subjects of less than 12 years of age, compared with older subjects. 
Together these results indicate that linked changes in antigen-
specific CD8+ T cells reflect ongoing activity of the autoimmune 
process occurring in type 1 diabetes after diagnosis, and that this is 
most pronounced in the young.
Discussion
To our knowledge, this is the first study to describe the longitudinal 
relationship between changes in β cell–specific CD8+ T cells and β 
cell function in patients with newly diagnosed type 1 diabetes. Here 
we show that changes in β cell–specific CD57+ effector memory 
CD8+ T cells in the blood reflect concomitant changes in stimulated 
C-peptide secretion occurring in the target tissue. Thus an expan-
sion of β cell–specific CD57+ effector memory CD8+ T cells is asso-
ciated with C-peptide retention, whereas a reduction of these cells 
is associated with C-peptide loss. This finding suggests that in the 
phase of type 1 diabetes that follows diagnosis, the effector mem-
ory compartment of the β cell–specific CD8+ T cell pool present in 
the circulation calibrates to changes in β cell function. This is an 
important finding, since it provides evidential support for periph-
eral blood measurements as indicators of tissue pathology in the 
setting of a complex autoimmune disease. This relationship is remi-
niscent of studies of postmortem pancreas samples from recent-
onset type 1 diabetes patients that reveal that CD8+ T cells are 
largely retained within the insulin-containing islets, but are absent 
from insulin-deficient islets (4). These observations in the tissues 
support the conclusion from our study that antigen load (secreted 
C-peptide as a measure of β cell function) drives the antigen- 
experienced CD8+ T cell response, and, in particular, tunes the 
reactivity to expand and retract populations of effector memory 
cells with gene and protein expression profiles that suggest 
enhanced cytolytic potential. Interestingly, we observed increases 
in C-peptide at 6 months in several patients, which were accompa-
nied by increases in β cell–specific effector memory CD57+ CD8+ T 
cells. This is likely to reflect the so-called honeymoon period expe-
rienced by some patients, during which endogenous β cell function 
recovers and there is greater C-peptide secretion and a reduced 
requirement for insulin by injection. We speculate that the func-
tional recovery of β cells promotes the appearance of CD57+ effector 
memory β cell–specific CD8+ T cells in the blood, via either differen-
tiation or proliferation, resulting in increased β cell killing by these 
cells, which in turns leads to waning of the cytotoxic T cell response.
Table 4. β Cell–specific CD8+ T cell subset canonical correlation 
coefficients
CD8+ T cell population Canonical correlation coefficient
GAD naive 2.794
GAD pre–terminal effector 1.905
GAD transitional memory 1.444
GAD central memory 1.402
GAD terminal effector 1.335
IA2 SCM 0.907
IA2 naive 0.873
InsB CD57– effector memory 0.842
IA2 CD57+ effector memory 0.831
IA2 transitional memory 0.759
IGRP pre–terminal effector 0.736
GAD CD57+ effector memory 0.600
InsB central memory 0.587
InsB pre–terminal effector 0.584
IGRP naive 0.465
IA2 central memory 0.431
InsB naive 0.408
GAD CD57– effector memory 0.399
GAD SCM 0.361
IGRP transitional memory 0.262
IGRP central memory 0.192
InsB terminal effector 0.130
IGRP CD57+ effector memory 0.099
IGRP terminal effector –0.006
IGRP CD57– effector memory –0.045
IGRP SCM –0.088
InsB CD57+ effector memory –0.108
IA2 terminal effector –0.126
IA2 CD57– effector memory –0.308
InsB SCM –0.333
PPI terminal effector –0.338
InsB transitional memory –0.375
PPI central memory –0.408
PPI CD57+ effector memory –0.470
IA2 pre–terminal effector –0.490
PPI SCM –0.549
PPI transitional memory –0.904
PPI pre–terminal effector –1.073
PPI CD57– effector memory –1.121
PPI naive –1.796
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Effector memory cells circulate in the blood and contain high 
levels of cytolytic molecules in order to respond rapidly to virus 
infections or eradicate tumor cells via targeted destruction. The 
finding that the effector memory compartment of β cell–specific 
CD8+ T cell populations correlates with C-peptide changes indi-
cates that this subset is important in driving disease. However, little 
is currently known about the dynamics and role of antigen-specific 
effector memory CD8+ T cells in type 1 diabetes pathology. Studies 
in nonobese diabetic mice have reported that CD8+ T cells specific 
for the islet antigen IGRP have an effector memory phenotype, 
which they acquire in the islets before emigrating to the periphery 
as stable effector memory cells (30, 31). Our study demonstrates 
a connection between β cell function in the islets and levels of β 
cell–specific CD57+ effector memory cells in the blood. Indeed, the 
network association modeling that we conducted indicates that 
immune changes are coordinated across multiple β cell specificities 
in a manner that is unrelated to responses against viruses. These 
data strongly imply a dialogue between the β cell and CD8+ T cells. 
This could arise directly, as a result of cognate interactions between 
target and effector cells in the tissues that result in spillover of cyto-
Figure 3. Gene and protein expression profiles indicate enhanced cytotoxic capability of CD57+ effector memory CD8+ T cells in type 1 diabetes patients. 
(A) RNA sequencing of CD57+ and CD57– effector memory CD8+ T cells. The top 5% differentially expressed genes are shown. (B) Volcano plot showing all 
genes upregulated (blue dots) and downregulated (red dots) in CD57+ compared with CD57– effector memory CD8+ T cells. Genes with Benjamini-Hochberg 
adjusted P ≤ 0.05 and absolute log2 fold change greater than 1 were considered significant. Differential expression analysis was performed with the 
DESeq2 package in R. Horizontal dashed line, FDR = 0.05; vertical dashed line, log2(fold change) = 1. (C) Significantly enriched gene ontology terms repre-
sented within differentially expressed genes. Gene ontology enrichment was performed using the R package clusterProfiler, and ontologies with adjusted 
P ≤ 0.05 were considered significant. (D) Protein expression of key differentially expressed genes in PPI-specific CD57+ and CD57– effector memory CD8+ 
T cells assessed by flow cytometry (n = 5 type 1 diabetes subjects). Bars and error bars represent means ± SD. Mann-Whitney test, *P < 0.05, **P < 0.01. 
MFI, mean fluorescence intensity.
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responses to the viruses analyzed. In addition, within this data set, 
we were limited to knowing baseline serological status for CMV 
and EBV, and within-study use of influenza vaccine in a small 
number of cases. Thus we have no insight into wild-type expo-
sures during the study, nor how to relate these to CD8+ T cell sub-
sets. Divergent CD8+ T cell responses are elicited depending on 
whether the virus is cleared, as in the case of acute infection with 
influenza virus; whether it persists as a latent virus undergoing 
periodic reactivation, as with EBV; or whether the virus induces a 
“smoldering” chronic infection characterized by pockets of ongo-
ing viral replication, as is the case for CMV (33–35). Furthermore, 
epitopes from lytic or latent proteins within a virus can influence 
the T cell response; for example, latent EBV epitopes elicit a mem-
ory CD8+ T cell response, whereas lytic epitopes drive a more dif-
ferentiated effector T cell phenotype (36). The potential role for 
viruses in type 1 diabetes development is controversial, has not 
previously been examined using this approach, and will clearly 
need closer inspection in future studies designed specifically to 
test viral hypotheses; but perhaps some initial conclusions can be 
drawn from our results. First, the data do not appear to support 
the role of a single virus, or a chronic infection, since this would 
be more likely to yield a virus- or subset-specific change similar to 
that observed for autoreactive CD8+ T cells. One interpretation is 
that antiviral responses have global influences on unrelated, con-
temporaneous autoimmune responses through bystander effects, 
and in this way contribute to islet pathology. Second, there is no 
lytically differentiated CD8+ T cells into the blood. Alternatively, it 
could arise indirectly, following cross-presentation of β cell auto-
antigens in secondary lymphoid organs resulting in cytotoxic CD8+ 
T cells entering the circulation. In either case, the CD57+ effector 
memory CD8+ T cells that are generated have enhanced cytolytic 
function and are immediately available for recruitment from the 
blood into islets where insulin content remains high. Thus, the 
autoreactive CD8+ T cell response in type 1 diabetes describes 
a process of calibration (levels change) and tuning (differentia-
tion status changes) that is characteristic of an adaptive immune 
response that is under the control of antigen. Our findings further 
emphasize how the disease may be tractable to an immunotherapy 
approach that limits the function of autoreactive activated CD8+ 
T cells. Indeed, this rationale provided the basis for the success-
ful use of alefacept, which preferentially engages memory CD8+ T 
cells, as an intervention in new-onset type 1 diabetes (32).
Unexpectedly, we also found that expansions in a small num-
ber of virus-specific memory CD8+ T cell subsets were associated 
with C-peptide loss. This finding contrasted with that for auto-
reactive CD8+ T cells in 2 respects: first, because a negative cor-
relation between virus-specific T cell subsets and C-peptide was 
the more typical finding; and second, because the involvement of 
specific subsets of virus-specific CD8+ T cells was less clear, sug-
gesting a more complex relationship. We observed considerable 
heterogeneity within the virus-specific T cell subsets associated 
with C-peptide change, probably reflecting diversity of immune 
Figure 4. Clonal TCR diversity and sharing are 
enhanced in CD57+ effector memory CD8+ T cells 
in type 1 diabetes patients. (A) TCRβ sequence 
diversity in CD57+ and CD57– effector memory 
(EM) CD8+ T cells. Wilcoxon test, *P < 0.05, n = 5. 
(B) Representation of TCRβ clones within CD57+ 
and CD57– EM CD8+ T cell samples given as a pro-
portion of the total number of clones. (C) TCRβ 
sequence sharing between CD57+ and CD57– EM 
CD8+ T cells within a subject (“CD57+ vs. CD57– EM 
within an individual,” n = 5), between CD57+ EM 
CD8+ T cells from different subjects (“CD57+ vs. 
CD57+ EM,” n = 20), between CD57+ and CD57– EM 
CD8+ T cells from different subjects (“CD57+ vs. 
CD57– EM,” n = 20), and between CD57+ EM CD8+ 
T cells from different subjects (“CD57– vs. CD57– 
EM,” n = 20). The top 285 represented clones in 
each sample were analyzed because the sample 
with the fewest clones had 285 clones. Wilcoxon 
test, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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after diagnosis compared with adults (13). Furthermore, age-
related differences in islet infiltration have been described, with 
younger subjects showing a greater infiltration of immune cells, 
including CD8+ T cells as well as B lymphocytes (5). In addition, 
peripheral blood CD4+ T cell autoreactivity shows a greater target 
antigen breadth in children than in adults, and is especially focused 
on proinsulin, as appears to be the case for CD8+ T cell responses 
in the present study (37). Thus the accentuated relationships we 
observe between β cells and CD8+ T cells in young children point 
to distinct underlying immunological pathways, with associated 
implications for immune monitoring and therapeutic approaches 
in this patient subgroup. It is tempting to speculate from these 
emerging studies that “classical” autoreactive, adaptive immune 
pathways (autoantibodies, autoreactive CD4+ and CD8+ T cells) 
have a greater influence over β cell loss in younger patients, and 
clear support for a virus–β cell cross-reactivity or mimicry process, 
since the network association modeling does not highlight any 
notable links between virus- and β cell–specific immune subset 
changes. Thus, it seems more likely that if viruses impact upon 
β cell loss, it relates to sporadic rather than continuous exposure 
(e.g., infection, immunization, or emergence of latent virus).
Notably, we found that relationships between autoreactive 
CD8+ T cells and C-peptide levels were considerably more pro-
nounced in children below 12 years of age compared with older 
subjects, suggesting that distinct pathogenic mechanisms operate 
in this younger age group in the period after diagnosis. Indeed, 
considerable disease heterogeneity has been observed in type 1 
diabetes patients based on their age at diagnosis. For example, 
children typically develop disease with more severe and rapid 
onset of symptoms and show a faster rate of C-peptide decline 
Figure 5. Visualization of the relationships between CD8+ T cell subsets over time. Pairwise correlations between CD8+ T cell subsets are displayed in 
a “network association plot” in which each T cell subset is represented by a node and nodes are connected by lines whose width is proportional to the 
strength of the correlation. Green lines indicate positive correlations and red lines indicate negative correlations. Nodes are also clustered on the strength 
of their correlations. Each CD8+ T cell subset is colored uniquely: naive (N), yellow; stem cell memory (SCM), gray; central memory (CM), light green; transi-
tional memory (TM), dark green; effector memory (EM)/CD57+ effector memory (CD57+ EM)/CD57– effector memory (CD57– EM), blue; pre–terminal effector 
(pre-TE), orange; terminal effector (TE), red; total tetramer-positive CD8+ T cell populations, white. The dashed oval highlights strong correlations between 
β cell–specific CD57+ effector memory CD8+ T cell subsets.
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in several autoimmune diseases, and, notably, in type 1 diabetes 
subjects accumulation of partially exhausted CD8+ T cells is asso-
ciated with a favorable response to anti-CD3 treatment (51, 52). 
The CD57-expressing CD8+ T cell population is heterogeneous 
and is composed of various functionally different subsets (50). 
To our knowledge, this is the first study to examine the phenotype 
of T cells that display or lack CD57 expression within the effec-
tor memory CD8+ T cell compartment. Our data indicate that the 
CD57-expressing effector memory CD8+ T cell subset is associated 
with enhanced cytotoxicity rather than an exhausted phenotype. In 
comparison with their CD57– counterparts, CD57+ effector memory 
CD8+ T cells did not show enhanced expression of genes associated 
with exhaustion in other studies, including KLRG1, LAG3, TIGIT, 
EOMES, CD160, PD-1, 4-1BB, CD244, CTLA4, PTGER2, LILRB4, 
CD160, CD86, NFAT, TIM3, TRAF1, IL10, TGFB, IL6, and SMAD2 
(47, 51, 52). In contrast, CD57+ effector memory CD8+ T cells dis-
played higher levels of genes such as GZMB, GZMH, KSP37, and 
GPR56, indicating an active potential for cytotoxicity in this subset.
Interestingly, we observed that both CD57+ and CD57– frac-
tions of the total effector memory CD8+ T cell pool contained T 
cells bearing common TCRβ sequences, which suggests that highly 
differentiated CD57+ effector memory T cells may arise from the 
CD57– effector memory T cell pool. Indeed, TCRβ sharing has 
been described between CD57+ and CD57– CD8+ T cells in healthy 
subjects (53). Furthermore, our RNA sequencing data indicate that 
the CD57– effector memory pool has properties of a self-renewing 
population of memory T cells expressing genes with the potential 
to replenish the cytolytically active CD57+ effector memory T cell 
compartment (54). Particular clonotypes were expanded within the 
total CD57+ effector memory CD8+ T cell fraction, and were highly 
shared between patients, hinting that effector memory T cells with 
particular specificities associated with disease may upregulate 
expression of CD57 in order to exert immediate effector functions 
and potentially contribute to β cell destruction.
In summary, through longitudinal tracking of β cell–reactive 
CD8+ T cell subsets in the blood alongside measurement of clini-
cally meaningful β cell function, we uncover a relationship that 
provides further support for a disease model in which the pres-
ence of β cells is a driver of cytotoxic autoimmunity. Interestingly, 
this functionality seems to reside within a clearly definable sub-
set of effector memory CD8+ T cells, the tracking of which in the 
blood using new technologies may assist in future development 
of useful surrogate markers of ongoing β cell damage in the tis-
our study can be considered to be consistent with this. However, 
this hypothesis should undergo further examination, since the 
numbers of subjects we studied are limited once they are binned 
into specific age ranges, and our study was not designed or pow-
ered to specifically address this question.
Expression of CD57 on the surface of CD8+ T cells increases 
during T cell differentiation and is considered to be a marker of 
cytotoxic function (26, 38–44). CD57 is expressed by heteroge-
neous populations of memory T cells and terminally differenti-
ated effector T cells (45, 46). In a previous study we observed that 
CD57 expression by β cell–specific CD8+ T cells was increased in 
type 1 diabetes patients compared with healthy controls, implicat-
ing CD57 as a disease-associated marker (8). In the present study 
we pinpoint the critical CD57-expressing T cell subset that asso-
ciates with β cell function. We report that CD57 expression is an 
important distinguishing feature of a particular subgroup of β cell–
specific effector memory T cells, the dynamics of which correlate 
with C-peptide changes in type 1 diabetes.
CD57 is considered to be a marker of antigen experience, and 
is one of several markers commonly used to define senescent and 
exhausted T cell states, which arise from repetitive or excessive 
and continuous stimulation, respectively, and display weak prolif-
erative capacity (47–49). However, it is known that cells express-
ing so-called “inhibitory” molecules such as CD57 can also exhibit 
higher cytotoxic activity and more pronounced cytokine produc-
tion than cells of a less differentiated phenotype (49, 50). T cell 
exhaustion has been identified as a beneficial prognostic indicator 
Table 5. Virus-specific CD8+ T cell subset canonical correlation 
coefficients
Virus-specific CD8+ T cell population Canonical coefficient
CMV naive 1.6631
CMV pre–terminal effector 1.1043
Influenza CD57+ effector memory 0.8071
CMV central memory 0.5338
EBV SCM 0.5031
CMV CD57+ effector memory 0.4853
CMV terminal effector 0.4773
Influenza terminal effector 0.4252
CMV transitional memory 0.3643
Influenza central memory 0.3344
Influenza transitional memory 0.3089
EBV terminal effector 0.2437
EBV transitional memory 0.2313
CMV SCM 0.2093
Influenza naive 0.1666
Influenza SCM 0.1529
EBV naive 0.126
EBV central memory 0.0823
EBV CD57– effector memory –0.106
EBV pre–terminal effector –0.1649
EBV CD57+ effector memory –0.294
Influenza pre–terminal effector –0.3717
CMV CD57– effector memory –0.4435
Influenza CD57– effector memory –0.5162
Table 6. Total CD8+ T cell subset canonical correlation scores
Total CD8+ T cell population Canonical coefficient
Central memory 0.1909
Transitional memory 0.1383
CD57– effector memory 0.0873
SCM 0.0631
Terminal effector 0.0616
Pre–terminal effector 0.0397
CD57+ effector memory 0.0047
Naive –0.2165
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appropriate time of the year. Response to immunization was deter-
mined through analysis of pre-dose and 4-weeks (± 7 days) post-dose 
samples (Supplemental Figure 3). We analyzed PBMCs taken at base-
line and 6, 12, 18, and 24 months after baseline visit. Individual tra-
jectories of 2-hour C-peptide area under the curve (AUC) over 2 years 
are shown in Supplemental Figure 3. All longitudinal PBMC samples 
obtained per patient were assayed on the same day in a single experi-
ment by an operator blinded to clinical data.
For RNA sequencing experiments, blood samples were taken 
from 5 HLA-A*24–positive males (mean age 29 years ± SD 5.5) with 
newly diagnosed type 1 diabetes (mean disease duration 8 months ± 
SD 4.6). For experiments for phenotyping of CD57+ and CD57– effec-
tor memory T cells by flow cytometry, blood samples were taken from 
10 HLA-A*02–positive subjects (56% female, mean age 31 years ± SD 
5.9) with newly diagnosed type 1 diabetes (mean disease duration 2.5 
months ± SD 1.7).
Measuring β cell function by MMTT. As per the TrialNet protocols, 
subjects underwent a 2-hour MMTT. Tests were started before 10 am, 
sues; and the targeting of which could be a promising strategy for 
arresting disease progression.
Methods
Subjects. Archived PBMC samples were obtained from 38 type 1 
diabetes patients who were enrolled in the placebo arms of 3 Trial-
Net studies (clinical trial registration numbers NCT00529399, 
NCT00505375, NCT00947427; for details see www.diabetestrialnet.
org). Demographic and baseline characteristics are reported in Sup-
plemental Tables 1 and 2. Entry requirement for all studies included a 
requirement for peak stimulated C-peptide by mixed meal tolerance 
test (MMTT) of ≥0.2 pmol/ml, positivity for at least 1 diabetes auto-
antibody, and type 1 diabetes diagnosis within 100 days of random-
ization. The age range spanned 6–34 years. Subjects were monitored 
for up to 2 years after randomization with regularly scheduled MMTTs 
to ensure tight glycemic control. Antibodies against CMV and EBV 
were assessed at screening. At months 2–11 inclusive, some subjects 
received annual clinically indicated killed influenza vaccine at the 
Figure 6. Canonical correlation analysis of CD8+ T cell subsets and C-peptide. The canonical correlation score represents a combination of multiple CD8+ T 
cell subset frequencies. The canonical correlation score is plotted against the log C-peptide change from baseline for each subject at each visit. Data from  
β cell–specific, virus-specific, or total CD8+ T cell data sets were used for separate canonical correlation analyses (CCAs). The correlation between the 
canonical correlation score and log C-peptide change from baseline was determined after adjustment for repeated measures. All subjects, n = 38; subjects 
<12 years old, n = 15; subjects ≥12 years old, n = 23.
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memory (TM; CCR7–CD45RA–CD27+), effector memory (EM; CCR7–
CD45RA–CD27–), effector memory populations defined by presence or 
absence of the activation marker CD57 (CD57+ EM/CD57– EM), pre– 
terminal effector (pre-TE; CCR7–CD45RA+CD27+), and terminal effec-
tor (TE; CCR7–CD45RA+CD27–). The gating strategy is illustrated in 
Supplemental Figure 4. Flow cytometry data were analyzed using FlowJo 
version 9.4 (Tree Star). To maximize capture of phenotypic data, each 
stain used 3 × 106 to 4 × 106 (HLA-A*0201 multimers) or 6 × 106 to 8 × 
106 PBMCs (HLA-A*2402 multimers), which is in excess of the number 
typically used for phenotyping of β cell–specific memory CD8+ T cells 
from ex vivo PBMC samples from type 1 diabetes patients (8, 58–60). 
A minimum of 1 × 104 live CD8+ T cells were collected for multimer 
analysis. Samples containing fewer than 1 × 104 live CD8+ T cells were 
excluded from the analysis. The mean number of live CD8+ T cells ana-
lyzed was 5.4 × 104 (SD 8.9 × 104), and the mean number of tetramer- 
positive CD8+ T cells per sample was 90 (SD 108).
In experiments for phenotyping CD57+ and CD57– effector mem-
ory T cells by flow cytometry, thawed PBMCs were incubated with 
LIVE/DEAD Aqua amine-reactive dye, dasatinib, CCR7 antibody, 
pHLA, and surface monoclonal antibodies/fluorophores as described 
above, with the exception that staining with CD95 PE was omitted. 
Instead PBMCs were stained with the surface monoclonal antibodies 
GPR56 PE, KLRG1 PE, and CD16 PE, and the intracellular antibodies 
granzyme B PE, KSP37 PE, and LAG3 PE (clones CG4, 14C2A0, 3G8, 
QA16A02, TDA3, and 11C3C65, respectively, all BioLegend). Stain-
ing with CD16 V500 was omitted when CD16 PE antibody was used. 
Intracellular staining was performed by fixing cells in Fixation Buffer 
(BioLegend) and washing cells with Intracellular Staining Perm Wash 
Buffer (BioLegend) according to the manufacturer’s instructions.
CD8+ T cell sorting for RNA sequencing. PBMCs were isolated on 
density gradients using Lymphoprep (Nycomed) and washed in RPMI 
supplemented with 2% human AB serum. PBMCs were washed and 
stained as above, and CD57+ and CD57– effector memory CD8+ T cells 
(gated as live CD14–CD16–CD19–CD4–CD3+CD8+CCR7–CD45RA–
CD27–) were sorted using a FACSAria (BD Biosciences) into BSA sup-
plemented with 10% BSA/5 mM EDTA.
RNA sequencing and data analysis. RNA was isolated immediately 
from cell pellets using the PicoPure RNA extraction kit (Thermo Fisher 
Scientific). cDNA was generated and amplified using the SMARTseq v4 
Ultra Low Input RNA Kit (Clontech) on the contactless Labcyte liquid 
handling system (Labcyte Inc.). Two hundred nanograms of amplified 
cDNA was used from each sample where possible to generate libraries 
using the Ovation Ultralow Library System V2 kit (NuGEN). In brief, 
cDNA was fragmented through sonication on Covaris E220 (Covaris 
Inc.), repaired, and polished followed by ligation of indexed adapters. 
Adapter-ligated cDNA was pooled before final amplification to add 
flow cell primers. Libraries were sequenced on HiSeq 2500 (Illumina 
Cambridge) for 100 paired-end cycles  in rapid mode.
Prealignment quality control for each sample, independently for 
forward and reverse reads, was performed using the stand-alone tool 
FastQC (BaseSpace Labs). Reads were trimmed using Trimmomatic 
(GenePattern) removing Illumina adapters and dropping reads shorter 
than 50 bases long. Reads were aligned to the reference genome (hg19) 
using HISAT2. PCR duplicates were removed using the MarkDupli-
cates function in Picard Tools (The Broad Institute). Counts were gen-
erated using HTSeq using human hg19 RefSeq from the University of 
California, Santa Cruz. Before differential gene expression analysis, 
fasting glucose was required to be 70–200 mg/dl, and long-acting 
insulin was permitted but no short-acting insulin (including no pump 
bolus) was allowed within 2 hours before start of test. A standard prep-
aration of fat, carbohydrate, and protein (Boost-HP, Nestle Health 
Care Nutrition Inc.) was used at a dose of 6 mg/kg to a maximum of 
360 ml. Two-hour C-peptide AUC was calculated using the trapezoi-
dal method over the initial 120-minute time period. Areas were then 
divided by 120 minutes for statistical analysis.
Tetramer assembly. Soluble, fluorochrome-conjugated peptide–
MHC class I tetramers were generated as described previously (55) 
to produce pHLA-A*02 and pHLA-A*24 tetramers. Tetramers were 
assembled over 5 separate 20-minute steps with the successive addi-
tion of streptavidin-APC (Life Technologies) to monomeric pHLA 
at a molar streptavidin/pHLA ratio of 1:4. PBS was added to give a 
final multimer concentration of 0.1 mg/ml pHLA content. Tetramers 
were stored in the dark at 4°C and used on the same day as assem-
bly. The peptide epitopes incorporated into the tetramers are sum-
marized in Table 1.
Cell staining and flow cytometry. PBMCs were thawed in a 37°C water 
bath until a pea-sized pellet of ice remained. Once completely thawed, 
cells were transferred from the cryovial to a 30-ml tube. Nine milliliters 
of 37°C thaw media (RPMI 1640 supplemented with 10% human serum) 
was added drop-wise to the cells while the tube was gently shaken. The 
cryovial was rinsed out with 1 ml thaw media and added drop-wise to 
the tube. Cells were centrifuged at 200 g for 8 minutes. The superna-
tant was discarded, the cell pellet was resuspended in 10 ml room-tem-
perature defrost media, and cells were counted. Cells were centrifuged 
at 400 g for 4 minutes and were transferred to flow cytometry tubes, 
washed with PBS, and stained with LIVE/DEAD Aqua amine-reactive 
dye (Invitrogen) for 10 minutes at room temperature, followed by wash-
ing with PBS. PBMCs were incubated with the protein kinase inhibitor 
dasatinib (Axon Medchem) at a final concentration of 50 nM for 30 min-
utes at 37°C to enhance the detection of low-avidity T cells (8, 56) and 
CCR7 BV421 monoclonal antibody (clone G043H7, BioLegend). Subse-
quently, PBMCs were stained for 10 minutes at 37°C with 1 μg of pHLA 
tetramer per tube. After washing with FACS buffer (PBS supplemented 
with 2% human AB serum and 3% FCS), PBMCs were stained with 
mouse anti-APC unconjugated monoclonal antibody (clone PE001, 
BioLegend) at a concentration of 10 mg/ml on ice for 20 minutes to 
stabilize binding of APC-labeled tetramers (57). After washing with 
FACS buffer, cells were stained with the following surface monoclo-
nal antibodies/fluorophores for 20 minutes on ice: CD3 BV785, CD8 
PECy7, CD27 BV605 (clones OKT3, SKI, O323, respectively, all Bio-
Legend); CD14 V500, CD16 V500, CD19 V500, CD45RA PE-CF594, 
CD95 PE, CD57 FITC (clones M5E2, 3G8, HIB19, HI100, DX2, NK-1, 
respectively, all BD Biosciences); CD4 PECy5.5 (clone S3.5, Invitrogen). 
Stained PBMCs were kept on ice and in the dark until acquisition on 
the same day on an LSRFortessa cell analyzer (BD Biosciences). The 
median percentage recovery of PBMCs from frozen samples was 98%, 
and the median viability was 100%. Gates to define tetramer positivity 
were set based on PBMC samples that were not stained with tetramer. No 
CD8+ T cells were stained in the absence of tetramers. Within the antigen-
specific CD8+ T cell populations and within the total CD8+ T cell popula-
tions, 9 CD8+ T cell subsets were assessed for analysis using the following 
cell surface marker combinations: naive (N; CCR7+CD45RA+CD27+CD57–
CD95–), stem cell memory–like (SCM; CCR7+CD45RA+CD27+CD57–
CD95+), central memory (CM; CCR7+CD45RA–CD27+), transitional 
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Canonical correlation analysis. Canonical correlation analysis 
(CCA) was used to determine a combination of T cell subset frequen-
cies most strongly correlated with log C-peptide change from base-
line. CCA is similar to principal components analysis (PCA) in that 
they both reduce the dimensionality of the data to a smaller number of 
independent components. However, whereas the components deter-
mined in PCA are meant to explain the greatest amount of variation in 
the data, the components in CCA are meant to have the greatest cor-
relation with a predicted variable (e.g., C-peptide). Thus, the CCA for 
CD8+ T cell subsets is a weighted combination of the subsets in which 
the weights have been selected to maximize the correlation of this new 
measurement with C-peptide change. In brief, CCA found a linear 
combination of variables (in this case, CD8+ T cell subset frequencies) 
that had the strongest correlation with an outcome variable (in this 
case, the log change in C-peptide from baseline) (63). CCA produced 
numerical coefficients for each of the variables (CD8+ T cell subsets). 
Then, for each subject in the study, a new variable was formed (typi-
cally referred to as a “score”) by multiplying each of the CD8+ T cell 
subset frequencies by the corresponding numerical coefficient and 
summing these products. Thus, the new variable is a combination of 
multiple CD8+ T cell subset frequencies, referred to as a “canonical 
correlation score.” Correlation and P values were adjusted for within-
subject correlation arising from repeated measures.
TCRβ sequence analysis. For TCRβ sequence analysis, true diver-
sity index was calculated using the tcR package. Sharing among TCR 
repertoires was quantified by calculation of the overlap coefficient 
[overlap (X, Y) = |X and Y|/min (|X|, |Y|)] for nucleotide sequences 
(species = nucleotide sequence). All statistical analyses were con-
ducted with SAS version 9.2 (SAS Institute) and R.
Study approval. All aspects of the study were approved by the 
South London Research Ethics Committee 5 (London, United King-
dom), REC reference 08/H0805/14, and the protocol and consent 
documents were approved by appropriate Independent Ethics Com-
mittees or Institutional Review Boards for participating TrialNet cen-
ters. All subjects or their parents gave written informed consent and 
assent as appropriate before study participation.
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genes with very low expression were discarded. Only genes with at least 
one count per million (before normalization) in at least 2 samples were 
used for downstream analysis in R and Bioconductor (61). Raw counts 
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method. Differential expression analysis was performed with the 
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Mixed-effects general linear model. The current study was a rigorously 
designed prospective analysis in which sample size was predetermined 
and the T cell populations to be studied were prespecified. The statis-
tical methodology and modeling used were developed and previously 
used for the analysis of the relationship between T cell subsets and ther-
apeutic effects of abatacept monotherapy in a clinical trial conducted 
by TrialNet (62). Sample size determinations for the present analy-
sis were based on data collected in the abatacept study. Relationships 
between T cell and C-peptide changes from baseline across time were 
analyzed with mixed-effects general linear models. T cell change from 
baseline at each visit was analyzed as the arithmetic change in T cell fre-
quency from baseline. C-peptide change from baseline at each visit was 
analyzed as the natural log of the ratio of C-peptide value to baseline 
value. Parameter estimates from the mixed-effects general linear model 
were used to estimate the log change in C-peptide change from base-
line per unit increase in T cell populations (i.e., the “slope”). This is not 
relevant to the individual subject, but to the “average” subject, and is in 
keeping with the definition of “regression.” Time in study (measured as 
months since baseline) was included in the model, and a variance com-
ponents error structure was assumed for the repeated measures across 
time. Hence, estimates and P values of the relationship between T cell 
and C-peptide (“slope”) have been adjusted for the effects of time and 
within-subject correlation. In addition, the model was also adjusted 
for subject age and baseline T cell population. Associations between 
changes in T cell subsets and C-peptide were considered significant at P 
< 0.05. To aid interpretation of the results, P values were also adjusted 
for multiple testing using the Benjamini-Hochberg method with a false 
discovery rate of 10%. Additionally, the model was used to evaluate 
the relationships between T cell population and C-peptide changes 
when subjects were divided into 3 age groups (<12 years, 12–17 years, 
>17 years). Although the youngest age group served as the referent, we 
report age-specific slopes and P values estimated from the fitted model.
Network association plot. Pairwise Pearson correlations and P values 
between T cell populations were computed after adjusting out correlation 
induced by time and within-subject correlation by correlating residuals 
from a repeated-measures model. These correlations were displayed in a 
“network association plot,” in which each T cell population is represented 
as a node and nodes are connected by lines whose width is proportional to 
the strength of the correlation. Further, our plot used “forced direction” 
to create a “spring plot,” in which nodes are also clustered on the strength 
of their correlations.
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